Hyderabad’s Biological E to get mRNA technology from WHO to produce Covid vaccines
No Comments
Hyderabad’s Biological E to get mRNA technology from WHO to produce Covid vaccines
Subject: Science
Section: Biotechnology
Context: Hyderabad-based vaccine manufacturer Biological E. Limited (BE) on Monday announced that it had been selected as a recipient of mRNA technology from the World Health Organisation (WHO) technology transfer hub.
Background: The company was selected by WHO’s Advisory Committee on Vaccine Product Development (ACPDV) after they examined a number of proposals from India.
mRNA vaccine technology transfer hub
- Announced on 21 June 2021, the objective of the technology transfer hub is to build capacity in low- and middle-income countries to produce mRNA vaccines through a centre of excellence and training (the mRNA vaccine technology hub). The hub is located at Afrigen, Cape Town, South Africa, and will work with a network of technology recipients (spokes) in low- and middle-income countries.
- How it will work ?
- Concretely, the Hub at Afrigen will share technology and technical know-how with local producers. WHO and partners will bring training and financial support to build the necessary human capital for production know-how, quality control and product regulation, and will assist where needed with the necessary licenses.
- The Hub and partners create a global common good for the benefit of all by providing a range of services along the entire vaccine value chain. Recipients will be able to contribute to the global effort to increase local vaccine production capacity, and may sign agreements with producers or develop vaccines locally.
WHO’s Advisory Committee on Vaccine Product Development (ACPDV)
- ACPDV is an independent standing WHO committee of experts which provides external advice to WHO related to priority infectious disease pathogens, associated vaccine and monoclonal antibody product development approaches and related manufacturing and delivery technologies.
- The committee’s remit covers disease areas where there is, or may be, substantial disease burden in low- and middle-income countries (LMICs), where no vaccine related products currently exist, but where there is ongoing product development activity which may benefit from WHO guidance, or technologies that could expedite availability and access of vaccine products in LMICs.
About mRNA Vaccine
https://optimizeias.com/mrna-vaccines/
About DNA based Vaccine